Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Drug developers switch gears to inhibit STING

Several biotechs are exploring STING inhibitors as a means to control innate immunity and inflammation.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sheridan, C. Drug developers switch gears to inhibit STING. Nat Biotechnol 37, 199–201 (2019). https://doi.org/10.1038/s41587-019-0060-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-019-0060-z

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing